JPMorgan analyst Jimmy Bhullar maintains Allstate (NYSE:ALL) with a Overweight and lowers the price target from $162 to $154.
JPMorgan lowers Allstate (NYSE:ALL) price target from $162 to $154 Read Post »
Citigroup analyst Michael Ward maintains Allstate (NYSE:ALL) with a Buy and lowers the price target from $138 to $135.
Citigroup lowers Allstate (NYSE:ALL) price target from $138 to $135 Read Post »
Piper Sandler analyst Nicole Miller Regan reiterates Allstate (NYSE:ALL) with a Overweight and maintains $137 price target.
Piper Sandler maintains Allstate (NYSE:ALL) $137 price target Read Post »
Barclays analyst Tracy Benguigui maintains Allstate (NYSE:ALL) with a Equal-Weight and lowers the price target from $115 to $113.
Barclays lowers Allstate (NYSE:ALL) price target from $115 to $113 Read Post »
Allstate (NYSE:ALL) Q2 Adj $(4.42) Misses $(4.04) Estimate, Sales $12.62B Beat $12.52B Estimate.
Allstate (NYSE:ALL) reported Q2 loss widened to $5.29 per diluted share from a loss of $3.80 a year earlier. Analysts surveyed by Capital IQ expected a loss of $4.82. Revenue for the quarter ended June 30 was $13.98 billion, up from $12.22 billion a year earlier. Three of four analysts surveyed by Capital IQ expected $13.36 billion.
Allstate (NYSE:ALL) Q2 Loss Widens, Revenue Rises Read Post »
Barclays analyst Lauren Lieberman maintains Procter & Gamble (NYSE:PG) with a Overweight and raises the price target from $160 to $166.
Barclays raises Procter & Gamble (NYSE:PG) price target from $160 to $166 Read Post »
Colgate-Palmolive (NYSE:CL) reported Q2 adjusted earnings Friday of $0.77 per diluted share, up from $0.72 a year earlier. Analysts polled by Capital IQ expected adjusted EPS of $0.75. Net sales for the quarter ended June 30 were $4.82 billion, compared with $4.48 billion a year earlier. Analysts surveyed by Capital IQ estimated $4.70 billion. Colgate-Palmolive said it now expects full-year EPS growth to be at the high end of mid-single-digits, compared with the previous forecast of a mid-single-digit growth, and a 5% to 8% increase in net sales compared with the initial estimate of a 3% to 6% increase. Analysts polled by Capital IQ estimate an adjusted EPS of $3.15 on revenue of $19.15 billion.
Colgate-Palmolive (NYSE:CL) Q2 Adjusted Earnings, Net Sales Climb Read Post »
Deutsche Bank analyst Steve Powers maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $88 to $91.
Deutsche Bank raises Colgate-Palmolive (NYSE:CL) price target from $88 to $91 Read Post »
RBC Capital analyst Nik Modi reiterates Colgate-Palmolive (NYSE:CL) with a Sector Perform and maintains $83 price target.
RBC Capital maintains Colgate-Palmolive (NYSE:CL) $83 price target Read Post »
Procter & Gamble (NYSE:PG) Price Target Raised to $170.00/Share From $165.00 by Wells Fargo.
UBS Raises Procter & Gamble (NYSE:PG) Price Target to $179 From $174, Maintains Buy Rating.
UBS Raises Procter & Gamble (NYSE:PG) Price Target to $179 From $174 Read Post »